Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptimizeD: Improving Outcomes in Depression in Primary Care
NCT05944926Phase 3Active, not recruiting
- Sponsor
- Harvard Medical School
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluoxetine in major depressive disorder (MDD), sponsored by Harvard Medical School. Started Mar 2024; status: active, not recruiting.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05944926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944926.